Kyowa Kirin Drug Patent Portfolio
Kyowa Kirin owns 1 orange book drug protected by 4 US patents Given below is the list of Kyowa Kirin's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US7727993 | Administering adenosine A2A receptor antagonist to reduce or suppress side effects of parkinson's disease therapy | 28 Jan, 2028 | Active |
US8318201 | Method of stabilizing diarylvinylene compound | 05 Sep, 2027 | Active |
US7541363 | Microcrystal | 13 Nov, 2024 | Expired |
US7727994 | Methods of treating patients suffering from movement disorders | 18 Jan, 2023 | Expired |
Latest Legal Activities on Kyowa Kirin's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Kyowa Kirin.
Activity | Date | Patent Number |
---|---|---|
Payment of Maintenance Fee, 12th Year, Large Entity | 15 May, 2024 | US8318201 |
Patent Term Extension Certificate
Critical
| 17 Oct, 2023 | US7727993 |
Notice of Final Determination -Eligible | 18 Jul, 2023 | US7727993 |
FDA Final Eligibility Letter
Critical
| 13 Jul, 2023 | US7727994 |
FDA Final Eligibility Letter
Critical
| 13 Jul, 2023 | US7727993 |
Interim Patent Term Extension Granted
Critical
| 22 Feb, 2023 | US7727993 |
Withdrawal of Application for PTE
Critical
| 22 Feb, 2023 | US7727994 |
transaction for FDA Determination of Regulatory Review Period | 07 Nov, 2022 | US7727993 |
transaction for FDA Determination of Regulatory Review Period | 07 Nov, 2022 | US7727994 |
Interim Patent Term Extension Granted
Critical
| 21 Sep, 2022 | US7727994 |
Interim Patent Term Extension Granted
Critical
| 21 Sep, 2022 | US7727993 |
Payment of Maintenance Fee, 12th Year, Large Entity | 17 Nov, 2021 | US7727993 |
Payment of Maintenance Fee, 12th Year, Large Entity | 17 Nov, 2021 | US7727994 |
Second letter to regulating agency to determine regulatory review period | 19 Feb, 2021 | US7727993 |
Second letter to regulating agency to determine regulatory review period | 19 Feb, 2021 | US7727994 |
Kyowa Kirin's Family Patents
Kyowa Kirin Drug List
Given below is the complete list of Kyowa Kirin's drugs and the patents protecting them.
1. Nourianz
Nourianz is protected by 4 patents, out of which 2 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US7727993 | Administering adenosine A2A receptor antagonist to reduce or suppress side effects of parkinson's disease therapy |
28 Jan, 2028
(3 years from now)
| Active |
US8318201 | Method of stabilizing diarylvinylene compound |
05 Sep, 2027
(2 years from now)
| Active |
US7541363 | Microcrystal |
13 Nov, 2024
(5 days ago)
| Expired |
US7727994 | Methods of treating patients suffering from movement disorders |
18 Jan, 2023
(1 year, 10 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nourianz's drug page